利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.024 秒)

    PROCESS FOR PREPARING HUMAN RELAXIN-2
    1.
    发明申请
    PROCESS FOR PREPARING HUMAN RELAXIN-2 有权
    制备人类赖氨酸-2的方法

    公开(公告)号：US20140328900A1

    公开(公告)日：2014-11-06

    申请号：US14234919

    申请日：2012-08-03

    申请人： Wolf-Georg Forssmann ,  Thomas Dschietzig ,  Ludger Ständker ,  Andreas Zgraja ,  Jochen Hirsch

    发明人： Wolf-Georg Forssmann ,  Thomas Dschietzig ,  Ludger Ständker ,  Andreas Zgraja ,  Jochen Hirsch

    IPC分类号： C07K14/64

    CPC分类号： C07K14/64 ,  Y02P20/55

    摘要： A process for preparing human relaxin-2 having the following amino acid sequence:A chain: (SEQ ID NO: 1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ ID NO: 2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps:providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH);effecting a chromatographic purification of the individual chains A and B after the solid state synthesis;followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; andsubsequent purification of the relaxin-2 formed.

    摘要翻译： 具有以下氨基酸序列的人松弛素-2的制备方法：A链：（SEQ ID NO：1）pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His-Val -Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B链：（SEQ ID NO：2）Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys- Leu-Cys-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-Met-Ser-Thr-Trp-Ser; 包括以下步骤：用通常的保护基提供合成A和B链所必需的氨基酸，其中半胱氨酸用作三苯甲基保护的氨基酸（L-Cys（Trt）-OH））; 在固态合成后进行单链A和B的色谱纯化; 然后在pH 7.9至8.4的同时折叠和组合各个链A和B在碳酸氢铵缓冲液中; 并随后纯化形成的松弛素-2。

    Process for preparing human relaxin-2
    2.
    发明授权
    Process for preparing human relaxin-2 有权
    人松弛素-2的制备方法

    公开(公告)号：US09434780B2

    公开(公告)日：2016-09-06

    申请号：US14234919

    申请日：2012-08-03

    申请人： Wolf-Georg Forssmann ,  Thomas Dschietzig ,  Ludger Ständker ,  Andreas Zgraja ,  Jochen Hirsch

    发明人： Wolf-Georg Forssmann ,  Thomas Dschietzig ,  Ludger Ständker ,  Andreas Zgraja ,  Jochen Hirsch

    IPC分类号： C07K14/64

    CPC分类号： C07K14/64 ,  Y02P20/55

    摘要： A process for preparing human relaxin-2 having the following amino acid sequence: A chain: (SEQ ID NO: 1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ ID NO: 2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps: providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH); effecting a chromatographic purification of the individual chains A and B after the solid state synthesis; followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; and subsequent purification of the relaxin-2 formed.

    RELAXIN FOR TREATING PATIENTS AFFLICTED OF IMPAIRED GLUCOSE TOLERANCE
    4.
    发明申请
    RELAXIN FOR TREATING PATIENTS AFFLICTED OF IMPAIRED GLUCOSE TOLERANCE 审中-公开
    用于治疗受影响的葡萄糖耐受性的患者

    公开(公告)号：US20150038411A1

    公开(公告)日：2015-02-05

    申请号：US14380163

    申请日：2013-02-22

    申请人： Thomas Dschietzig

    发明人： Thomas Dschietzig

    IPC分类号： A61K38/22

    CPC分类号： A61K38/2221 ,  A61K9/0019 ,  A61K9/1647

    摘要： A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed.

    摘要翻译： 用于治疗患有葡萄糖耐量降低或有风险的药物组合物（IGT）和/或II型，其包含有效量的用于保护β-细胞的松弛素和针对高血液效应的β-细胞功能 葡萄糖（葡萄糖毒性）。 对2型糖尿病患者治疗糖尿病患者和保护胰岛细胞和β细胞功能的β细胞进行了分类。